All In Biotech

Drug Trial Radar · NCT07646353

First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults

A First-in-Human Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4425689A in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Apr 10, 2028

Study completion Apr 10, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.

Conditions

  • Malaria, Falciparum

Interventions

  • GSK4425689A SCBiological

    Participants receive GSK4425689A SC.

  • GSK4425689A IVBiological

    Participants receive GSK4425689A IV.

  • PlaceboDrug

    Participants receive Placebo in the same volume and route as the participants receiving GSK4425689A in the same cohort.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) overall and by severityTime frame: From Day 1 up to Day 364
  2. Number of participants with serious adverse events (SAEs) overall and by severityTime frame: From Day -28 [informed consent form (ICF) signing] up to Day 364

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.